摘要
目的:探讨诱导性多能干细胞(i PS细胞)来源的嵌合体胸腺移植(TT)对异基因骨髓移植小鼠的T细胞重建和移植物抗宿主病(GVHD)的影响。方法:将i PS细胞来源的嵌合体胸腺,植入异基因骨髓内骨髓移植(IBM-BMT)受体小鼠的肾被膜下,4周后分析比较IBM-BMT组、IBM-BMT+TT组、IBM-BMT+淋巴细胞输注(DLI)组的T细胞亚群、GVHD临床评分和病理学检查。结果:IBM-BMT组、IBM-BMT+TT组、IBM-BMT+DLI组外周血CD8+T细胞比例分别为(5.52±0.83)%、(11.10±1.49)%、(8.49±0.82)%,组间差异有统计学意义(P<0.05)。IBM-BMT+TT组的CD4+T细胞比例为(9.60±0.69)%,高于IBM-BMT组(6.42±1.40)%和IBM-BMT+DLI组(8.07±0.65)%(P<0.05)。IBM-BMT组、IBM-BMT+TT的GVHD评分低于IBM-BMT+DLI组,病理表现更轻。结论:i PS细胞来源的嵌合体胸腺移植,能有效加快移植后T细胞重建,并抑制GVHD反应。
Objective To explore the effects of iPS cells-derived chimeric thymus transplantation on T cells reconstitution and graft versus host disease of routine after allo-BMT. Methods iPS cells-derived chimeric thymus was grafted under the renal capsules of mice after aliogeneic IBM-BMT. The mice were divided into three groups: IBM-BMT group, IBM-BMT + TT group and IBM-BMT + DLI group. Four weeks after BMT, T lymphocyte subsets in the peripheral blood were analyzed by flow cytometry, the degree and pathological examination of GVHD were observed, respectively. Results Percentage of CD8 + T cells in IBM-BMT group, IBM-BMT + TT group and IBM-BMT + DLI group was (5.52 ± 0.83)%, (11.10 ± 1.49)% and (8.49 ± 0.82)% respectively, there was significant difference between pairwise comparisons (P 〈 0.05 ), and percentage of CD4 + T cells of the peripheral blood in IBM-BMT + TT group (9.60 ± 0.69)% was significantly higher than IBM-BMT group (6.42 ±1.40)% and IBM- BMT + DLI group (8.07 ± 0.65)% (P〈 0.05) . IBM-BMT group and IBM-BMT + TT group showed less clinical and histopathological scoring of GVHD than IBM-BMT + DLI group. Conclusion iPS cells-derived chimeric thymus transplantation could effectively accelerate T cells reconstitution and prevent GVHD after allo-BMT.
出处
《实用医学杂志》
CAS
北大核心
2017年第9期1414-1418,共5页
The Journal of Practical Medicine
基金
国家自然科学基金(编号:81270632
81302544)
广东省扬帆计划引进紧缺拔尖人才项目(编号:201433004)
广东医学院人才引进人员科研启动项目(编号:B2013015)
留学人员科技活动项目择优资助(编号:2QT14002)
关键词
诱导性多能干细胞
异基因骨髓移植
胸腺移植
T细胞重建
移植物抗宿主病
Induced pluripotent stem cell
Allogeneic bone marrow transplantation
Thymus transplan- tation
T cells reconstitution
Graft versus host disease